市場調查報告書

皮膚T細胞淋巴瘤市場 - 成長,趨勢,預測

Cutaneous T-cell Lymphoma Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 921271
出版日期 內容資訊 英文 114 Pages
商品交期: 2-3個工作天內
價格
皮膚T細胞淋巴瘤市場 - 成長,趨勢,預測 Cutaneous T-cell Lymphoma Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 114 Pages
簡介

淋巴瘤由於癌症發生率的上升和老年人口的增加等,市場擴大。皮膚T細胞淋巴瘤(CTCL),在皮膚淋巴瘤中是最常見的類型。診斷出皮膚淋巴瘤的4人中有3人以上是CTCL。CTCL最常見的2個類型,是早期生長緩慢的蕈狀肉芽腫,和比CTCL更具侵略性的Sezary症候群(SS)。根據皮膚淋巴瘤基金會的說法,CTCL是稀少的疾病群,美國每年約有3,000名新病例報告,約有1萬6,000∼2萬名美國人罹患蕈狀肉芽腫。CTCL50歲以上的老年人比年輕人多,女性比男性發病多,非洲系美國人的發病率認為是最高。

本報告提供皮膚T細胞淋巴瘤的世界市場調查,市場概要,各類型,各地區的市場趨勢,市場規模的變化與預測,市場促進、阻礙因素以及市場機會分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 新加入廠商的威脅
    • 消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各類型
    • 蕈狀肉芽腫(MF)
    • Sezary症候群(SS)
    • 其他
  • 各治療
    • 放射線治療
    • 化療
    • 免疫療法
    • 標靶治療
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Bausch Health
    • Celgene Corporation
    • Helsinn Healthcare SA
    • Kyowa Hakko Kirin Co., Ltd.
    • Merck & Co., Inc.
    • Seattle Genetics
    • Soligenix, Inc.

第7章 市場機會及未來趨勢

目錄
Product Code: 67114

Market Overview

Certain factors that are driving the market growth include the rise in lymphoma cancer incidence and a growing geriatric population.

Cutaneous T-cell lymphomas (CTCL) are the most common types of skin lymphoma. More than 3 out of every 4 skin lymphomas diagnosed are CTCLs. The two most common types of CTCL are mycosis fungoides (MF), which is slow-growing in the early stages, and Sezary Syndrome (SS), which is a more aggressive form of CTCL. According to Cutaneous Lymphoma Foundation, CTCL is a rare family of diseases, with approximately 3,000 new cases reported in the United States every year and about 16,000 - 20,000 Americans have mycosis fungoides. CTCL is more common in patients older than 50 years of age compared to younger people and it develops more often in men than in women, with the highest incidence rates being reported amongst African-Americans.

Scope of the Report

As per the scope of the report, Cutaneous T-cell Lymphomas (CTCL), also known as skin T-cell lymphomas, are a group of disorders characterized by abnormal accumulation of malignant T-cells in the skin. CTCL are cancers of the T lymphocytes that primarily involve the skin resulting in the development of rashes, plaques, and tumors. CTCL also involves the blood, lymph nodes, and other internal organs.

Key Market Trends

Mycosis Fungoides Segment is Expected to Register a Significant Growth in the Forecast Years

By type, the market has been segmented into Mycosis Fungoides (MF), Sezary Syndrome (SS) and others. Mycosis Fungoides is the most frequent type of cutaneous T-cell lymphoma which usually involves the skin and grows slowly over many years. It is very difficult to diagnose, especially in the early stages. MF is more common in men compared to women, in blacks compared to whites, and in patients, older than 50 years of age compared to younger people. In addition, sezary syndrome is considered to be the second most common type of CTCL and characterized by the presence of lymphoma cells in the blood.

North America dominates the Cutaneous T- cell Lymphoma Market

North America dominates the market owing to the upsurge in the demand for progressive treatment options and early adoption of new technologies. CTCL is the rare form of T-cell lymphoma. There are about 3,000 new cases of CTCL in the U.S. each year. Europe and the Asia Pacific are followed next after North America owing to the presence of a diversified patient pool, emerging economies, and a rise in the collaboration of domestic and international companies in these regions, thus driving this market.

Competitive Landscape

The market studied is moderately competitive and consists of several major players. Some of the key players in the cutaneous T-cell lymphoma market include Bausch Health Companies Inc., Celgene Corporation, Helsinn Healthcare SA, Kyowa Hakko Kirin Co., Ltd., Merck & Co. Inc., Seattle Genetics, and Soligenix, Inc., which are having a presence internationally and provide these products across the globe.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Lymphoma Cancer Incidence
    • 4.2.2 Growing Geriatric Population
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Treatment
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Mycosis Fungoides (MF)
    • 5.1.2 Sezary Syndrome (SS)
    • 5.1.3 Others
  • 5.2 By Treatment
    • 5.2.1 Radiation Therapy
    • 5.2.2 Chemotherapy
    • 5.2.3 Immunotherapy
    • 5.2.4 Targeted therapy
    • 5.2.5 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bausch Health
    • 6.1.2 Celgene Corporation
    • 6.1.3 Helsinn Healthcare SA
    • 6.1.4 Kyowa Hakko Kirin Co., Ltd.
    • 6.1.5 Merck & Co., Inc.
    • 6.1.6 Seattle Genetics
    • 6.1.7 Soligenix, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS